Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Belotero Balance + lidocaine is a sterile, injectable dermal filler composed of cross-linked hyaluronic acid (22.5 mg/mL) and 0.3% lidocaine hydrochloride in a physiologic phosphate buffer[2][5][6]. The hyaluronic acid is produced by bacterial fermentation (Streptococcus equi), then cross-linked using BDDE via cohesive polydensified matrix (CPM) technology to create a soft, cohesive gel[1][2]. The addition of lidocaine provides local anesthesia to reduce pain during injection[1][4]. It is indicated for the correction of moderate-to-severe facial wrinkles and folds such as nasolabial folds, marionette lines, perioral lines, oral commissures; it is also used for lip enhancement and volume augmentation in the infraorbital hollow in adults over 21 years old[2][6]. The product is administered by injection into the mid-to-deep dermis or submucosal/subcutaneous tissue depending on indication. Developed and manufactured by Merz Aesthetics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Belotero Balance + lidocaine.